1. Home
  2. SRTA vs FBRX Comparison

SRTA vs FBRX Comparison

Compare SRTA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SRTA

Strata Critical Medical Inc.

HOLD

Current Price

$5.53

Market Cap

425.3M

Sector

N/A

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$24.38

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTA
FBRX
Founded
2014
N/A
Country
United States
United States
Employees
601
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.3M
487.2M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SRTA
FBRX
Price
$5.53
$24.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$7.81
$67.00
AVG Volume (30 Days)
741.8K
349.0K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$39.27
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
$9.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.85
$7.00
52 Week High
$6.02
$35.80

Technical Indicators

Market Signals
Indicator
SRTA
FBRX
Relative Strength Index (RSI) 69.70 37.61
Support Level $4.08 $22.33
Resistance Level $5.99 $34.44
Average True Range (ATR) 0.30 2.17
MACD 0.06 -0.55
Stochastic Oscillator 93.89 4.45

Price Performance

Historical Comparison
SRTA
FBRX

About SRTA Strata Critical Medical Inc.

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: